Atea Pharmaceuticals, Inc.
AVIRNasdaqHealthcare · Pharmaceutical Preparations · MA · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351.4M | $48.6M |
| Operating income | −$180.9M | −$192.9M | −$164.2M | −$130.7M | $138.4M | −$11.0M |
| Net income | −$158.3M | −$168.4M | −$136.0M | −$115.9M | $121.2M | −$10.9M |
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M | $863.6M |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M | $315.8M |
| Equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M | $547.8M |
| EPS (diluted) | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 | $-0.51 |
| Shares out. | 85.5M | 84.2M | 83.3M | 83.2M | 82.7M | 82.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −57.5%
- Return on assets
- −50.2%
- Return on capital (ROCE)
- −65.7%
- Liabilities / assets
- 12.6%
- Debt / equity
- 0.14×
- Book value / share
- $3.22
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.65safe
- Accruals / assets
- −8.3%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-05Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
- Phase 1Recruitingreadout ~2026-06Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
- Phase 3Active Not Recruitingreadout ~2026-09C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
- Phase 3Recruitingreadout ~2026-12C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Bml Investment Partners, L.P.Activist (13D)Feb 9, 2026
- Sommadossi Jean-PierrePassive (13G)May 14, 2025
- Blackrock, Inc.Passive (13G)Apr 23, 2025
- Radoff Bradley LouisActivist (13D)Apr 17, 2025
- Ecor1 Capital, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Hammond Janet MjOfficer — Chief Development Officer | Jan 31, 2026 | Option exercise | 58,050 | — |
| Corcoran AndreaOfficer — See Remarks | Jan 31, 2026 | Option exercise | 54,866 | — |
| Sommadossi Jean-PierreOfficer — President, CEO, and Chairman | Jan 31, 2026 | Option exercise | 272,983 | — |
| Foster WayneOfficer — EVP, Chief Accounting Officer | Jan 31, 2026 | Option exercise | 41,333 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 7.6M | 19.7 | +1.4% |
| Apr 30, 2026 | 7.5M | 28.5 | -2.6% |
| Apr 15, 2026 | 7.7M | 22.2 | +1.3% |
| Mar 31, 2026 | 7.6M | 15.6 | -5.1% |
| Mar 13, 2026 | 8.0M | 9.9 | +1.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Results of operationsMar 5, 2026
- Results of operationsJan 8, 2026
- Results of operationsNov 12, 2025
- Results of operationsAug 7, 2025
- Shareholder voteJun 20, 2025
- Results of operationsMay 12, 2025
- Entered a material agreement · Results of operations · Director / officer change · Regulation FD disclosureApr 17, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4/AMay 21, 2026
- 4May 20, 2026
- 10-QMay 12, 2026
- 8-KMay 12, 2026
- SCHEDULE 13G/AMay 6, 2026
- DEFA14AApr 27, 2026
- DEF 14AApr 27, 2026
- SCHEDULE 13G/AMar 26, 2026
- 4Mar 13, 2026
- 10-KMar 5, 2026
- 8-KMar 5, 2026
- SCHEDULE 13GFeb 9, 2026
- 4Feb 3, 2026
- 4Feb 3, 2026
- 4Feb 3, 2026